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ABSTRACT 
Atrial fibrillation is the most common cardiac arrhythmias, and a major cause of morbidity and mortality due to 
cardioembolic stroke. The left atrial appendage is the major site of thrombus formation in non-valvular atrial fi-
brillation. Loss of atrial systole in atrial fibrillation and increased relative risk of associated stroke point strongly 
toward a role for stasis of blood in left atrial thrombosis, although thrombus formation is multifactorial, and much 
more than blood flow irregularities are implicated. Oral anticoagulation with vitamin-K-antagonists is currently 
the most effective prophylaxis for stroke in atrial fibrillation. Unfortunately, this treatment is often contraindi-
cated, particularly in the elderly, in whom risk of stroke is high. Moreover, given the risk of major bleeding, there 
is reason to be skeptical of the net benefit when warfarin is used in those patients. This work reviews the patho-
physiology of cardioembolic stroke and critically spotlights the current status of preventive anticoagulation the-
rapy. Various techniques to exclude the left atrial appendage from circulation were discussed as a considerable 
alternative for stroke prophylaxis. (Korean Circ J 2009;39:443-458) 
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Introduction 
 
Atrial fibrillation (AF) is the most common cardiac 
rhythm disturbance observed in clinical practice, and 
has numerous potential complications; of these, stroke 
is the most serious and life threatening. Prevalence of 
AF increases with age, up to 15% in octogenerians, and 
continues to grow rapidly due to the increasing pro-
portion of aging in the population. Moreover, the el-
derly population of today has a higher prevalence of 
predisposing conditions for AF, such as diabetes, heart 
failure, hypertension, and coronary heart disease.
1-6) 
Lifetime risk for development of AF is 1 in 4 for men 
and women 40 years of age and older.
7) 
Absence of a regular contraction of the fibrillating 
atria leads to an increase of atrial pressure and dilata-
tion, which, together with hemoconcentration,
8)9) endo-
thelial dysfunction, and a prothrombotic state, is pre-
requisite for thrombus formation.
10) Echocardiography 
and autopsy studies have shown that more than 90% of 
all thrombi in patients with AF originating in the left 
atrium form in the left atrial appendage (LAA).
11-15) 
Consequently, LA thrombi are responsible for at least 
one fourth of ischemic stroke, which is more frequently 
associated with persistent and severe disability, compar-
ed to ischemic events attributable to vascular disease.
16-19) 
Associated mortality is 27% in 12 months, and a five 
year recurrence rate of up to 34%.
6) Socio-economical 
dimensions of this disease, therefore, are relevant. 
The main risk of an embolic event in patients with 
atrial fibrillation is lack of adequate oral anticoagulation 
(OAC). Vitamin-K-antagonists (VKA) are highly effective 
for stroke prevention in patients with AF, but a sub-
stantial number of patients are not eligible for chronic 
therapy with coumadines due to their narrow therapeu-
tic range and bleeding complications that are potentially 
fatal. Even eligible patients may have reservations about 
long-term OAC with VKA, due to the need for contin-
uous laboratory monitoring and possible interactions 
with food, drugs, and individual lifestyle. Patients at 
high risk of embolic stroke, but with contraindications 
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for OAC are in a need of an alternative approach that is 
not associated with long-term risk of hemorrhage or 
other attendant circumstances. This is particularly true 
for those who have survived intracranial hemorrhage 
but remain at high risk for cardiogenic embolism. A rea-
sonable alternative may be exclusion of the LAA cavity 
from circulation, using either surgical or percutaneous 
catheter-based procedures. Currently, excision of the 
LAA at the time of mitral valve surgery is recommended 
for reduction of future stroke risk.
20) Efficacy of LAA ex-
clusion in patients undergoing elective coronary artery 
bypass graft surgery was shown in the LAA Occlusion 
Study (LAAOS).
21) 
In this review, we discuss pathophysiology of throm-
bogenesis in the LAA, and its consequential role in AF-
related embolic stroke. Further emphasis is put on te-
chnical and clinical data from different percutaneous 
transcatheter devices for occlusion of the LAA for pro-
tection of cardiogenic embolism. 
 
Anatomy and Function  
of the Left Atrial Appendage 
 
The LAA is a long, tubular, often multilobed and tra-
beculated stucture, a remnant of the embryonic left 
atrium (LA), whereas the smooth LA cavity is derived 
from an outgrowth of the pulmonary veins.
22) The ori-
fice of the LAA is oval in shape, located between the left 
ventricle and the left upper pulmonary vein. The body 
of the appendage extends over the atrioventricular groove 
and the surface of the left ventricle, towards the left cir-
cumflex artery and the great cardiac vein in an anterior 
direction.
23-25) LAA structure was initially characterized 
from 1,842 autopsy hearts.
26) Anatomy of the LAA is 
complex and varies considerably in terms of volume 
(0.7-19.2 mL), length (16-51 mm), and size of the orifice 
(5-40 mm).
25)27)28) The structure of the cardiac muscle 
cells of the LAA appears similar to that of the surround-
ing myocardium.
29) The muscular mass of the LAA con-
tains the majority of cardiac atrial natriuretic factor 
(ANF).
30) ANF increases sodium excretion, diuresis, and 
natriuresis, and, thus, opposes the sodium-conserving 
actions of the renin-angiotensin-aldosterone system.
31) 
Tabata et al.
32) found that the most important factor in-
creasing plasma concentration of ANF in patients with 
left-sided cardiac dysfunction is distension of the LAA 
wall. Moreover, stretch sensitive receptors within the 
LAA are involved in regulation of heart rate.
33) 
After primary ex vivo characterization of LAA anatomy, 
use of transoesophageal echocardiography (TOE) has 
made clear in vivo imaging of the LAA possible, so that 
its size, shape, flow patterns, and content can be assess-
ed in health and disease.
34-37) However, due to its varia-
ble and complex anatomy, standard definitions of to-
mographic imaging planes are nearly impossible. On the 
other hand, assessment of LAA function by Doppler 
echocardiography and detection of LAA spontaneous 
echocardiographic contrast (SEC) is of considerable cli-
nical relevance. New insights into LAA anatomy, in terms 
of angulation and motility, have recently been provided 
by computed tomography, which also confirmed the 
echocardiographic finding of a broad interindividual 
variation in LAA morphology.
38-40) Also, using magnetic 
resonance imaging, three dimensional analysis of the 
LAA is possible and will be of considerable interest in the 
future, due to avoidance of radiation for the patient.
41) 
In sinus rhythm, the LAA shortens to a greater extent 
than the rest of the left atrium and has a distinct pat-
tern of contraction,
34) although this seems to be of minor 
importance for overall cardiac performance.
42) Consider-
ing emptying and filling waves, TOE Doppler flow wi-
thin the LAA was described as quadriphasic in the ma-
jority of healthy subjects with sinus rhythm.
43)44) In AF 
without thrombus, the LAA appears to empty passively 
and fill with multiple small fibrillatory contractions that 
do not contribute to LV filling. LA pressure is the essen-
tial determinant of LAA flow. Hence, the magnitude of 
LAA filling and emptying is influenced primarily by 
both left ventricular function and heart rate.
43)44) The-
refore, in a heart disease state with both increased atrial 
and left ventricular end diastolic pressure, the LAA may 
compensate for consequent volume overload due to its 
distensibility.
45)46) 
 
Thrombogenesis in Atrial Fibrillation 
 
The LAA is the site most commonly associated with 
thrombus formation, particularly in patients with non-
valvular AF.
11-15)47)48) A multivariable analysis of cohorts 
followed prospectively in clinical trials and other care 
settings revealed that thrombi have been identified using 
TOE in 15-20% of patients with AF who have clinical 
risk factors for ischemic stroke.
12)48) Pathogenesis of LAA 
thrombus formation has not been fully elucidated, but 
the precondition is likely to result from a hypercoagula-
ble state explained by Virchow’s triad of thrombogenesis- 
i. e., abnormal changes of the vessel wall, blood flow, 
and blood constituents.
49)50) Nowadays, this is translated 
as follows: “Abnormal blood flow” refers to reduced flow 
up to stasis due to lack of contraction in combination 
with increased volume and size of the LAA; “abnormal 
blood constituents” are represented by activated coagu-
lation factors and platelets, and “abnormal vessel wall” 
in this case refers to structural and functional changes 
of endothelial or endocardial cells. 
 
Abnormal blood flow 
Volume and size of the LAA increases in atrial fibril-
lation in what is termed as atrial remodeling.
34)38)48)51) 
Larger LA and LAA sizes are associated with lower LAA  
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flow velocity
47) and risk of ischemic stroke.
52)53) Dimi-
nished contractility of the appendage understandably 
leads to reduction of blood flow as well,
34)42) which is 
associated with increased thrombogenicity within this 
trabeculated blind spot.
50)54)55) Notably, risk of ischemic 
stroke due to diminished LAA flow appears not to be 
related to the underlying cardiac rhythm which led to 
the consideration of LAA velocity as a surrogate para-
meter for risk stratification.
56) Under conditions of low 
LAA blood flow, SEC may occur on TOE
47)48)50)56-59) in 
strong association with LAA thrombus formation and 
systemic embolism.
15)52)60-64) SEC is thought to be related 
to an intensified interaction between fibrinogen and 
erythrocytes,
65) but a low level of hemoglobin is not as-
sociated with lower prevalence of SEC when controlled 
for clinical and echocardiographic variables.
66) Density 
of SEC increases and LAA velocities show significant 
and progressive decline together with accumulation of 
clinical risk factors for stroke, as evaluated by the CH-
ADS2 score (see below).
67) Furthermore, there is a high 
likelyhood of cerebral embolism and death, despite an-
ticoagulant therapy, in patients with low LAA emptying 
velocity and dense SEC.
68)69) It is important to note that 
anticoagulation does not influence the presence of SEC 
because it does not change underlying hemodynamic 
abnormalities. In chronic congestive heart failure (CHF), 
there is a negative correlation between LAA emptying 
velocity, LV ejection fraction, and LV end-diastolic pres-
sure, possibly explaining the increased incidence of st-
roke in patients with atrial fibrillation and CHF.
70-74) 
Furthermore, independent predictors for the presence 
of thrombus and dense SEC included left ventricular 
ejection fraction <40% and left atrial dimension >50 
mm.
75) 
 
Abnormal blood constituents 
Presence of a LA thrombus is a result of a dynamic 
process of coagulation activation and fibrinolysis. The-
refore, a high fibrin turnover is a cause rather than a 
consequence of cardiogenic embolism in patients with 
AF, in whom laboratory markers of both activated coa-
gulation and impaired fibrinolysis can be found.
49) Pro-
thrombin fragments 1+2
50)76) and thrombin-antithrom-
bin-complexes (TAT),
50)57) as a measure of thrombin ge-
neration, as well as markers for platelet activation,
50) are 
increased in AF. Elevated D-dimer plasma levels indicat-
ing increased fibrin formation and degradation
50)57)76-79) 
are independently predictive of the presence of LAA 
thrombi on TOE,
80) and, most importantly, are associat-
ed with future thromboembolic events.
72)81) Initiation of 
OAC reduces D-dimer values;79)82) however, in patients 
with thromboembolism, these values remain at a higher 
level compared to those without events.
72) This led to the 
assumption that, comparable to the diagnostic algori-
thm in deep vein thrombosis/pulmonary embolism, D-
dimers could be helpful in predicting the absence of 
LAA thrombi in patients with AF.
80)83)84) Activation of 
coagulation is directly related to diminished LAA func-
tion, in that an inverse correlation was shown between 
both LAA flow velocities and LAA diameter, and TAT 
as well as D-dimer.
57)85)86) Tissue factor expression in-
duced by local inflammation is involved in pathogenesis 
of thrombosis in patients with nonvalvular atrial fibril-
lation.
87) Levels of coagulation activation markers also rise, 
together with the number of risk factors for stroke.
88-90) 
SEC visible on TOE shows a significant correlation to 
prothrombin fragments 1+2, D-dimer, and TAT.
91) 
Studies on the fibrinolytic system in AF are few, and 
conflicting results regarding clinical relevance have been 
reported, which may be due to the natural course of the 
fibrinolytic response to coagulation activation. Hyperfi-
brinolysis as a consequence of a strong coagulation stim-
ulus is more likely in early inflammatory states than in 
later or chronic states, where predominance of inhibitors 
leads to hypofibrinolysis.
92) Tissue type plasminogen ac-
tivator (tPA) plays a crucial role in inititation of fibri-
nolysis and can be found in elevated levels in AF.
93) Plas-
min is the most important component of the fibrinoly-
tic system generated in response to thrombin formation, 
but it is rapidly inactivated by α2-antiplasmin. The acti-
vator-inhibitor-complex (plasmin-α2-antiplasmin; PAP) 
has a short half-life in plasma, and therefore indicates 
recent fibrinolytic activity.
94) In a subgroup of patients 
enrolled in the Stroke Prevention in Atrial Fibrillation 
(SPAF) III study, PAP levels in patients with AF were 
associated with clinical characteristics predictive of th-
romboembolism, including older age and reduced LV 
function.
95) PAP levels are also elevated in acute stroke
96) 
and myocardial infarction,
97) and may therefore indicate 
nonspecific cell damage, inflammation, and endothelial 
dysfunction. The same is true for both tissue plasmino-
gen activator (t-PA) and its inhibitor (PAI-1),
72)98) which 
can be correlated with severity of inflammatory disor-
ders.
99) 
The significance of platelet activation in atrial fibrilla-
tion is uncertain and may also be seen in the light of a 
nonspecific inflammatory reaction. Procoagulant mem-
brane vesicles derived from activated platelets, known as 
microparticles, are elevated in patients with conditions 
that are associated with atrial fibrillation (e. g., hyperten-
sion, coronary artery disease, diabetes, stroke).
100) Solu-
ble sP-selectin is well known as a marker of platelet acti-
vation and is elevated in the plasma of patients with 
AF.
50)74)101-105) Recently, Choudhury et al.
100) found that 
both AF patients and disease control subjects had signi-
ficantly higher levels of platelet derived microparticles 
and sP-selectin compared to healthy control subjects; 
however, there was no difference between AF patients 
and disease control subjects. β-thromboglobulin is ano-
ther platelet-specific protein that indicates activation and  
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another examplary representative of flow-dependent he-
mostatic activation, as it was found to be highest in pa-
tients with the lowest LAA flow velocities and the grea-
test atrial dilatation.
85) Plasma levels of β-thromboglo-
bulin are dependent on duration of AF, and showed a 
significant increase 12 hours after onset of paroxysmal 
AF.
106) It is worthy of mention that results concerning 
the effect of antithrombotic treatment on markers of 
platelet activation in AF have been uncertain. In studies 
by Kamath et al.
107)108) treatment with warfarin or aspirin 
either failed to demonstrate any significant benefit on 
platelet activation (β-thromboglobulin, sP-selectin), 
or showed an effect in favor of aspirin on the absolute 
amount of P-selectin per platelet in patients with AF.
108) 
The clinical significance of this finding remains to be 
elucidated. Likewise, the prognostic relevance of platelet 
activation in terms of future thromboembolic events is 
ambivalent. A substudy of the SPAF III trial revealed no 
association,
103) whereas the Rotterdam study found plas-
ma levels of sP-selectin to be predictive of clinical adverse 
outcomes in AF.
104) On the whole, evidence of platelet 
activation in AF patients seems most likely due to under-
lying cardiovascular disease, rather than arrhythmia per se. 
 
Abnormal endothelium and endocardium 
Further insight into the hypercoagulable state in atrial 
fibrillation is provided by studies of von Willebrand 
factor (vWF), a hemostatic mediator involved in platelet 
aggregation and clot stabilization, derived from endo-
thelial cells and thrombocytes.
109) Endothelial activation 
or disturbance is indexed by elevated plasma levels of 
vWF.
110) Increased plasma vWF can be found in patients 
with AF,
50)76)78)79)86)105)111) and tends to increase further 
with concomitant heart failure.
74) Most important, the 
level of vWF is intimately related to recognized inde-
pendent risk factors for stroke (heart failure, age, dia-
betes, previous stroke) and might itself be predictive of 
future stroke.
102)112)113) As expected, increased plasma levels 
of vWF were found to be associated with presence of 
LAA thrombus, visible by TOE,
50) whereas Fukuchi et 
al.
114) found a significant correlation between degree of 
endocardial expression of vWF and extent of platelet 
adhesion/thrombus formation in the LAA. Endocar-
dial overexpression of vWF may occur during the process 
of atrial structural remodeling in chronic AF.
115)116) These 
structural changes also affect the extracellular matrix
117)118) 
and, therefore, the system of matrix metalloproteinases 
(MMP). There are hints to a link between the MMP sys-
tem and a prothrombic state.
119) 
Increased levels of circulating endothelial cells (CEC) 
have been demonstrated in conditions associated with 
endothelial damage.
120) Freestone et al.
111) found that 
CEC levels in patients with AF and an acute cardiovas-
cular or cerebrovascular event were significantly elevated 
compared to patients with stable, chronic AF. Therefore, 
in the interim balance, it can be stated that AF itself is 
the major contributory factor to thrombogenesis, which 
implies activation of the coagulation cascade, rather than 
platelets, and is the key to excess thromboembolic risk 
in AF. 
 
Stroke-Risk Asessment 
in Atrial Fibrillation 
 
Risk of stroke varies considerably among patients with 
AF. On the one hand, individual risk for stroke must be 
considered prior to prescription of VKA for anticoagu-
lation; on the other hand, risk of stroke must be outwei-
ghted against the risk of bleeding and burden on the 
patient due to the need for continuous laboratory INR 
monitoring or possible interactions associated with food, 
drugs, and individual lifestyle or preferences.
121) Several 
stroke risk stratification schemes are available to help 
clinicians with this decision.
68)122-125) Two useful resources 
stand out in clinical practice: The Framingham risk score, 
derived by Wang et al.,
68) and the CHADS2 score pu-
blished by Gage et al.
123) Both use a five step calculation 
to predict the risk for stroke in patients with AF. The 
former considers age, gender, systolic blood pressure, dia-
betes, and prior stroke or TIA. Each category is assigned 
different grading, and predicts 5-year stroke risk in the 
absence of anticoagulation. Concerning the latter, the 
C stands for recent congestive heart failure, the H for 
hypertension, the A for age 75 or older, the D for dia-
betes, and the S for prior stroke or TIA. Each category 
is assigned one point, except for stroke or TIA, which re-
ceives two points due to high association with subsequent 
stroke. A high score on this index correlates with raised 
annual stroke rate. The CHADS2 score may be easier to 
use, but is less precise.
126) 
 
The Effect of Cardioversion 
 
One of the theoretic benefits of cardioversion in pa-
tients with AF is the assumption that restoring normal 
atrial electromechanical activity may diminish the risk 
of cardiogenic thromboembolism and, therefore, spare 
the need for anticoagulation. However, there is a body 
of evidence to demonstrate that a temporary worsening 
of LAA function (“stunning”) after cardioversion is re-
sponsible for development of new clots.
127)128) The hall-
mark of LAA stunning is reduction of post cardiover-
sion LAA flow velocity in sinus rhythm compared to 
those in AF, regardless of iatrogenic (electrical or ph-
armocological) or spontaneous cardioversion.
129)130) Even 
after succesful restoration of sinus rhythm, SEC can be 
seen in up to 37% of patients after 3 months,
131) indi-
cating the persistence of a hypercoagulable state after 
cardioversion.
78)132) The strategy of rhythm control has 
been directly compared with simple rate control in se- 
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veral randomized clinical trials. In a pooled analysis, fre-
quency of ischemic stroke in the group of patients as-
signed to rate control was comparable to that of patients 
assigned to rhythm control.
133) It is amazing, therefore, 
that Cox et al.
134) reported on 306 patients who un-
derwent the maze procedure for treatment of medically 
refractory atrial fibrillation. Only 2 perioperative strokes 
occurred, and in 265 patients followed up to 11.5 years 
after the maze procedure, there was only one late minor 
stroke, which has since been completely resolved. On 
the one hand, this good result may be explained by pre-
dominance of sinus rhythm, and, on the other hand, by 
the absence of the LAA and restoration of left atrial me-
chanical function.
135) 
Hypothetically, restoring mechanical activity to the 
LAA with cardioversion may also result in systemic em-
bolism due to wash out of pre-existing LAA thrombi, 
which may explain the occurence of stroke shortly after 
treatment.
136)137) The Assessment of Cardioversion Using 
Transesophageal Echocardiography (ACUTE) trial
138) 
compared a TOE-guided strategy combined with short-
term anticoagulation using a conventional 3-week oral 
anticoagulation pre cardioversion strategy. Although 
there was significant difference in the composite end 
point of major and minor bleeding and a shorter time 
to cardioversion, there was no difference in the compo-
site end point of stroke, transient ischemic attack, and 
peripheral embolism. Therefore, current guidelines for 
cardioversion in patients with atrial fibrillation lasting 
longer than 48 hours recommend coumadin treatment 
for at least three weeks prior to cardioversion, and for a 
minimum of four weeks afterward. Alternatively, perfor-
mance of a cardioversion without anticoagulation is jus-
tifiable if direct previous TOE shows no thrombi present 
in the LAA.
121)  
 
Cardiac Imaging for 
Thrombus Detection 
 
During the past thirty years, TOE has become a valu-
able tool for diagnosis of thrombus within the appenda-
ge by allowing semi-invasive, highly accurate imaging of 
the LAA.
139) It is, therefore, an essential part of the gui-
delines for management of AF,
121) and the modality of 
choice for detecting LA or LAA thrombi with a sensiti-
vity and specificity of approximately 95% to 100%.
127) 
Nevertheless, detection of LAA thrombus is prone to 
misdiagnosis because clots may remain hidden due to 
the three-dimensional complexity of the LAA, and a 
false-positive diagnosis of thrombus may stem from false 
interpretation of a prominent pectinate muscle. The 
aforementioned sensitivity and specificity regarding 
thrombus detection by TOE was found in comparison 
with intraoperative observations;13) however, no compa-
rison has been made using direct left atrial angiography. 
Sensitivity for thrombus detection during the left ven-
tricular phase of pulmonary angiogram was found to be 
100% compared to later surgical inspection.
140) In our 
own experience with transcatheter LAA occlusion and by 
means of direct angiography, we detected LAA thrombi 
not seen with simultaneously performed TOE in ap-
proximately 10% of patients (Fig. 1).
141) Furthermore, we 
revealed additional LAA lobes in some patients during 
repeated LAA angiography. The “collapsed” lobes seem 
to be “blown up” by contrast injections into the LAA. 
Consequently, in these cases, the procedure was halted 
and postponed, causing inconvenience and additional 
risk for patients, as well as increased overall treatment 
costs. Furthermore, this finding strengthens the hypo-
thesis of cardiac embolism due to wash out of pre-exist-
ing LAA thrombi after successful cardioversion. Hence, 
an imaging modality with higher accuracy of preproce-
dural LAA thrombus detection would be very helpful 
for planning of LAA occlusion procedures. Further te-
chnical development of echocardiography seems pro-
mising. Recent introduction of an RT-m3D TOE trans-
ducer permits virtually instantaneous 3D imaging while 
preserving spatial and temporal resolution, thereby sig-
nificantly enhancing visualization of complex 3D struc-
tures such as the LAA.
142) Further improvement of B-
mode image quality of 3D-TOE will be available in the 
near future. The combination of tissue doppler imaging 
and use of contrast agents may help to better characte-
rize thrombogenic structures within the LAA.
58) Also, 
with respect to LAA imaging, few studies using MRI 
Fig. 1. Angiographic contrast filling defect in the contast shadow
of the LAA (white arrows) indicating a spherical thrombus, which
was not diagnosed by TOE. Note the TOE probe at the left mar-
gin and the loop of the pigtail catheter (striped arrow), indicating
the position of the aortic valve. LAA: left atrial appendage, TOE:
transoesophageal echocardiography.  
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and spiral CT scan have been reported on detection of 
thrombus and SEC.
38)39)143-146) Regarding LAA occlusion 
procedures, the advantages of cardiac CT/MRA include 
the following: 1) preprocedural imaging of the anatomi-
cal characteristics of the LAA and neighbouring atrial 
structures; 2) assessment of the anatomical relationship 
of the LA, esophagus, and adjacent vascular structures; 
3) postprocedural detection of structural and functional 
changes of the LA and LAA.
147) 
 
Oral Anticoagulation: Therapeutic 
Gold Standard in Atrial Fibrillation 
 
Of the VKAs, warfarin is the most widely used and 
investigated coumarin derivative, exerting its anticoag-
ulant effect through modulation of c-carboxylation of 
glutamic acid (GLA) residues of the vitamin K-depen-
dent coagulation factors II, VII, IX, and X, resulting in 
production of coagulation factors with reduced coagulant 
capacity.
148)149) Dose adjusted (INR 2.0-3.0) OAC is well 
established in patients with nonvalvular AF, and has 
been associated with a decreased risk of cardioembolic 
events of greater than 60%.
150)151) Effectiveness of OAC 
depends on intensity of treatment,
77) in that insufficient 
doses of anticoagulants reduce the therapeutic benefit, 
while excessive anticoagulation increases the risk of bleed-
ing.
152) The benefit of dose adjusted OAC is confirmed 
by a significant decrease of markers of coagulation acti-
vation,
72)79) whereas fixed low-dose warfarin or aspirin-
warfarin combination treatment did not substantially 
reduce markers of thrombogenesis.
153) Despite the pro-
ven benefit, OAC with warfarin or other VKA remains 
underused in clinical practice,
154) although underutiliza-
tion implies that a decision not to use warfarin is rea-
ched after assessment of the balance between benefit 
(prevention of thromboembolic stroke) and risk (bleed-
ing), which suggests a net benefit. With regard to anti-
thrombotic therapy, there are two groups of AF patients: 
Those with no contraindications for therapy who never 
received warfarin, and those who are on therapy, but with 
an INR below or above the range of 2.0-3.0, having in-
creased risk for either stroke or bleeding. Overall, 55% 
of warfarin-eligible patients actually use the drug, with 
the lowest rates seen in the oldest patients-those at high-
est risk of stroke.
155)156) In the United States, AF patients 
on warfarin spend only about one-half of the time within 
therapeutic INR range,
157-159) and of those patients ad-
mitted to hospital with a stroke while receiving warfarin 
therapy, most have subtherapeutic international nor-
malized ratios.
160)161) Leckey et al.
162) found that only 13% 
of patients with ischemic stroke and known AF before 
stroke were taking warfarin. Considering the worst case 
scenario, that half of patients are untreated and the other 
half are out of range 50 percent of the time, only one 
fourth receive optimal treatment. 
Review of the literature has identified several barriers 
to prescription of VKA, which are related to the patient, 
the physician, and the health care system.
163) One of the 
strongest patient related predictors of warfarin withhold-
ing is age. Warfarin use increases with a history of ische-
mic stroke, and decreases with age >80 years. The most 
important physician related reasons not to anticoagulate 
include 1) the perception of benefit vs. risk of therapy, 
insofar as the risk for embolism, relative to hemorrhage, 
is judged to be lower, and 2) the relative contraindication 
to therapy due to lack of patient reliability or patient 
noncompliance as a reason for difficulties in monitor-
ing the prothrombin ratio.
163) 
Acetylsalicylic acid (ASA, Aspirin) as an anticoagulant 
has some advantages over warfarin. These include sub-
stantially less potential for drug-drug or drug-diet inter-
actions, a wider therapeutic index, and no need for INR-
monitoring. For AF patients with increased risk of bleed-
ing, it is often prescribed instead of warfarin on the pre-
sumption that it is safer. A meta-analysis of six random-
ized controlled trials suggests that ASA does reduce the 
risk for ischemic stroke in AF (22% relative risk reduc-
tion for ASA compared with placebo).
12)164) It is notewor-
thy that only one of these trials {the Stroke Prevention 
in Atrial Fibrillation (SPAF) study
165)} reported a statis-
tically significant difference. Recently, the Birmingham 
Atrial Fibrillation Treatment of the Aged Study, BAF-
TA,
166) reaffirmed that warfarin is superior to ASA in 
stroke prevention. On the other hand, the risk of major 
hemorrhage, including hemorrhagic stroke, was similar 
in both aspirin (2.0% per year) and warfarin (1.9% per 
year) treated patients. The authors recommended use of 
anticoagulation (warfarin) for all people over 75 years 
who have atrial fibrillation, unless there are contraindi-
cations, or the patient decides that the size of the benefit 
is not worth the inconvenience of the treatment.
165) 
 
Bleeding Risk Under 
Oral Anticoagulation 
 
The emphasis on avoidance of hemorrhagic stroke or 
traumatic intracranial hemorrhage and other iatrogenic 
events may cause physicians and patients to choose the-
rapy that minimizes side effects, rather than therapy that 
maximizes benefit. In association with anticoagulation, 
bleeding is the complication of greatest concern; there-
fore, selection of appropriate therapy should weigh ad-
vantages and disadvantages carefully.
167) In anticoagulat-
ed patients, annual risk of major bleeding, meaning a 
hemorrhage requiring >2 units of blood or requiring 
hospitalization, ranges between 1.1-1.7% and 0.3-0.6% 
for intracranial hemorrhage.
124)168) However, this low level 
of risk has rarely been replicated in contemporary stu-
dies, and then, perhaps, only in patients who are stable 
on long-term anticoagulation. Higher rates of hemor- 
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rhage were found in the Stroke Prevention in Atrial Fi-
brillation II Study, which consisted of 2 parallel trials of 
patients aged >75 years and ≤75 years.
169) Annual rates 
of major bleeding were 4.2% and 1.7%, respectively. 
Hylek and coworkers
170) studied a cohort of 472 patients 
of whom one third were ≥80 years of age, compared 
with a total of 20 patients >75 years in the pooled an-
alysis of 5 randomized trials that proved efficacy of 
anticoagulation,
150) and 91% had ≥1 stroke risk factor. 
Cumulative incidence of major hemorrhage for patients 
≥80 years of age was 13.1 per 100 person-years and 4.7 
for those <80 years of age (p=0.009). Thus, the increas-
ing risk of bleeding with increasing age is clearly dem-
onstrated in this study. Moreover, during the first 90 
days of warfarin treatment, age ≥80 years and interna-
tional normalized ratio (INR) ≥4.0 were associated with 
increased risk, despite trial-level anticoagulation control. 
Within the first year, 26% of patients who were ≥80 
years of age stopped taking warfarin. Perceived safety 
issues accounted for 81% of them. The most obvious 
results to be emphasized from this study are that the risk 
of major hemorrhage increases by a factor of 10-fold 
between CHADS2 scores of 0 and ≥4, and also that 
warfarin termination was highest among patients with 
CHADS2 scores ≥3.
170) The finding that bleeding risk 
is highest within the first year of therapy was confirmed 
by results from the ACTIVE-W study: annual risk of 
major hemorrhage over the duration of the study is 
quoted as 2.6% and 2.0% for warfarin-naive and warfa-
rin-experienced patients, respectively. In contrast, the 
risks are more like 6% to 7% and 4%, respectively, in 
the first year.
171) Moreover, an ancillary analysis from the 
ACTIVE-W trial reports that risk of major bleeding dur-
ing OAC was lower among patients with a CHADS2 
score of 1 (1.36% per year) compared with CHADS2 >1 
(2.75% per year).
172) 
The following patient characteristics are considered 
risk factors for anticoagulation-related bleeding compli-
cations: Advanced age, uncontrolled hypertension, his-
tory of myocardial infarction or ischemic heart disease, 
cerebrovascular disease, anemia or a history of bleeding, 
and concomittant use of other drugs, such as antiplatelet 
agents.
173) Moreover, primary clinical and health-related 
problems associated with typical geriatric syndrome in 
older adults, and which make the decision regarding use 
VKA more complex, include functional decline, frailty 
and falls, polypharmacy, nutritional deficiencies, and 
cognitive dysfunction.
167) All of these conditions are of-
ten cited as reasons to preclude the elderly from antico-
agulation.
174) A prospective observational study of 207 
AF patients in an acute-care setting hospital, assessing 
frail and non-frail patients, demonstrated that frail pa-
tients were less likely to receive warfarin, both on hos-
pital admission and on discharge. Notably, such patients 
at the same time were at greater risk of experiencing em-
bolic stroke (12.3% vs. 3.9% in frail and non-frail pa-
tients). Aronow et al.
175) described 312 AF patients with 
an average age of 84 years residing in a chronic care fa-
cility. Rates of stroke over three years in those not anti-
coagulated were 56% in those with no prior history of 
thromboembolism and 81% in those with prior history 
of thromboembolism. These frail patients also had a 
tendency to sustain a greater risk of major/severe he-
morrhage, as well as greater mortality.
176) 
Comparable to existing stroke risk stratification sche-
mes, there are bleeding risk models:177-182) Beyth and 
coworkers
178) identified four independent risk factors for 
bleeding: Age ≥65 years, history of GI bleeding, his-
tory of stroke, and one or more of four specific comorbid 
conditions. They found a cumulative incidence of major 
bleeding at 48 months of 53% in high-risk paitients 
(three or four risk factors), 12% in middle-risk patients 
(one or two risk factors), and 3% in low-risk patients 
(no risk factors). Kuijer and colleagues
179) developed 
another prediction model based on age, gender, and 
presence of malignancy. In patients classified at high, 
middle, and low risk, frequency of major bleeding was 
7%, 4%, and 1%, respectively, after 3 months of therapy. 
Comparable bleeding rates for comparable risk classes 
were found by Shireman et al.
181) (5.4%, 2.0%, and 0.9%, 
respectively, after 90 days of treatment) using the fol-
lowing criteria: Age >70 years, gender, remote bleeding, 
recent bleeding, alcohol/drug abuse, diabetes, anemia, 
and antiplatelet use. Gage et al.
182) gave 2 points for a 
prior bleed and 1 point for each of 10 further stroke risk 
factors, and claimed the highest accuracy of all other 
bleed prediction schemes. Nevertheless, none of these 
risk prediction schemes has been fully validated in large 
prospective AF patient cohorts. 
The outlined clinical complexity of pathophysiology 
and prevention of thromboembolism in AF patients is 
most impressively illustrated by the fact that those at 
highest risk of stroke, and, therefore with the greatest 
need for antithrombotic therapy, also experience the most 
bleeding. Thus, an alternative that combines high efficacy 
in stroke prevention with low risk of bleeding is warranted. 
 
Left Atrial Appendage Occlusion 
for Stroke Risk Reduction 
 
The frequency of thrombus formation in the LAA of 
patients with AF and its suspected role as a source of 
embolism led to the hypothesis that resection or obli-
teration of the LAA might reduce the risk of stroke. 
Hellerstein et al.
183) was the first to show the feasibility 
of LAA resection in dogs. The first resection of the LAA 
for prophylaxis of recurrent arterial embolism in men 
was performed in 1949 by Madden,
184) followed by Beal 
et al.
185) in 1950. Johnson and coworkers performed 
atrial appendectomies in 437 patients during cardiac  
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surgery. No strokes were attributed to AF, and no pa-
tients were found to have atrial clots on TOE during 
follow-up.
4) Odell and coworkers
186) demonstrated in 
dogs and human cadavers that thoracoscopic exclusion 
of the LAA using either a stapler or an endoloop is also 
feasible and effective; Blackshear and colleagues
187) eval-
uated left atrial appendage obliteration in 14 high-risk 
patients with atrial fibrillation who had clinical risk 
factors for stroke and an absolute contraindication to or 
failure of prior thrombosis prevention with warfarin. 
One fatal stroke occurred 55 months after surgery, and 
one non-disabling stroke occurred three months after 
surgery. For the LAA Occlusion Study,
21)188) 77 patients 
with risk factors for stroke were randomized to either 
LAA occlusion or control (52 patients for LAA occlu-
sion, 25 patients in the control group) at the time of cor-
onary artery bypass graft (CABG). Two patients (2.6%), 
both randomized to the LAA occlusion group, had pe-
rioperative thromboembolic events: One had an intrao-
perative ischemic stroke, and the other a TIA occurring 
on the third postoperative day. The former patient was 
in AF and had echocardiographic evidence of a patent 
foramen ovale and bilateral carotid stenoses. After a 
mean follow-up of 13±7 months, no further strokes or 
TIAs occured in the LAA occlusion group.
21) Nonethe-
less, surgical or thoracoscopic LAA closure, other than 
as an adjunctive procedure, as recommended by ACC 
guidelines
20) in patients undergoing mitral valve surgery, 
has not been enthusiastically accepted due to its invasive 
nature. Thus, based on surgical experience, development 
of a less invasive percutaneous approach to close the 
LAA by implantation of a mechanical device was a lo-
gical consequence.
189)190) 
 
The Percutaneous Left Atrial Appendage Trans-
catheter Occlusion system 
The Percutaneous Left Atrial Appendage Transcathe-
ter Occlusion (PLAATO)  (EV3, Inc., Plymouth, MN, 
USA) device was the first to be successfully deployed for 
use in humans,
191) but was withdrawn from the market 
by the manufacturer in 2006. The PLAATO system con-
sists of an implant and a delivery catheter. The implant 
is a self-expanding nitinol cage covered with an occlu-
sive expanded polytetrafluoroethylene membrane. The 
expanded membrane has intimate contact with the inner 
wall of the appendage, so that complete closure of the 
ostium can be achieved. The diameter of the nitinol cage 
ranges from 15 to 32 mm. Small hooklets along the struts 
and passing through the membrane assist with device 
anchoring. The device was delivered through a custom 
12 Fr transseptal sheath curved to point at the left atrial 
appendage. 
Several reports demonstrate efficiacy in stroke pre-
vention using PLAATO (Table 1). 
However, related serious adverse events occurred in 
every patient cohort procedure; these included vessel 
perforation during vascular access and cardiac tampo-
nade after transseptal puncture. Some patients experi-
enced pericardial effusions, which were mostly uneven-
tful, but also lead to pericardiocentesis and a prolonged 
hospital stay. The worst case in our series was a peripro-
cedural death due to device embolization, resulting in 
acute occlusion of the left ventricular outflow tract. Im-
plant anchoring in another patient appeared unstable in 
LA angiography, so that the device was explanted, and 
the LAA of the patient was occluded by open heart sur-
gery on the catheter table.
194) Our LAA occlusion pro-
gram was halted following these disastrous cases, and 
extensive revision was undertaken for all 73 prior im-
plantations. As a result, we discovered a rotation of the 
device at the moment of release from the delivery sys-
tem in a significant number of cases which resulted in 
loss of contact between parts of the anchor rows and 
the LAA wall (unpublished observation). One further 
theoretical concern was de novo formation of thrombi 
on the atrial surface of the implant which, to the best of 
our knowledge, has never been reported on the basis of 
clinical data. Nevertheless, there are conflicting results 
concerning formation of neo-endothelium on the de-
vice, which is the prerequisite to absence of thrombo-
genicity. Post mortem analysis by Omran et al.
198) dem-
onstrated a PLAATO device completely covered by ne-
oendothelium on the atrial surface one year after implan-
tation, whereas we found no endothelialization of the 
luminal side 2.5 years after LAA occlusion.
199) 
 
The Watchman Left Atrial Appendage system 
The second device specifically designed for percuta-
neous transcatheter LAA exclusion is the Watchman 
Left Atrial Appendage System (Atritech Inc., Plymouth, 
MN, USA). This three-part system consists of a trans-
septal sheath, a delivery catheter, and an implantable 
Table 1. Currently published data for stroke prevention using the PLAATO system
Author (Ref.#)  Patient No  Follow-up  Estimated annual stroke rate  Actual annual stroke rate
Block et al.
192)193)  064 5  years  6.6%  3.3% 
Park et al.
194)  073 2  years  5.0%  0.0% 
Ussia et al.
195)  020 40±10 month  6.4%  0.0% 
De Meester et al.
196)  010 3±47 month  7.1%  0.0% 
Ostermeyer et al.
197) 111  9.8  month  6.3%  2.2% 
PLAATO: Percutaneous Left Atrial Appendage Transcatheter Occlusio  
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device. The implant is a selfexpanding nitinol frame 
structure with fixation barbs and a permeable polyester 
fabric that covers the atrial side, and is available in dia-
meters ranging from 21-33 mm. The device has been 
implanted since 2002 in Europe and since 2003 in the 
United States.
200) Two patients experienced device em-
bolization; both implants were successfully retrieved per-
cutaneously. Five pericardial effusions (two of them need-
ing pericardiocentesis) and one major air embolism oc-
curred without long-term sequelae. The WATCHMAN 
Left Atrial Appendage System for Embolic PROTEC-
Tion in Patients With Atrial Fibrillation (PROTECT 
AF) study was designed to demonstrate safety, efficacy, 
and non-inferiority of the WATCHMAN device against 
chronic warfarin therapy in patients with nonvalvular 
atrial fibrillation who are eligible for long-term OAC.
201)202) 
Of 707 patients enrolled, 463 were randomly assigned 
to LAA closure and 244 to warfarin therapy. The device 
was successfully implanted in 91% of the patients in 
whom it was attempted. Patients were followed for an 
aggregate of 1,065 patient-years. After 6 months, 355 
(92%) of patients with an implanted device were able to 
discontinue warfarin therapy. For the control group, 
plasma warfarin concentration was in the therapeutic 
INR range (between 2.0 and 3.0) 66% of the time. Rate 
of ischemic stroke was higher in the intervention group 
than in the control group. Five patients had periproce-
dural events, mainly air embolism. After the periproce-
dural timeframe, ischemic stroke occurred in nine pa-
tients in the intervention group, compared with six pa-
tients in the control group. In both groups, all ischemic 
strokes that had INR measurements available at the time 
of the event occurred at a subtherapeutic INR level. He-
morrhagic strokes were less frequent in the intervention 
group than in the control group. Five of the six hemorr-
hagic strokes in the control group were fatal, and all oc-
curred in patients with therapeutic INR levels. Device 
embolisation occurred in three patients; one was noted 
during the procedure and two were discovered by TEE 
on day 45. One device embolisation was removed per-
cutaneously by use of a vascular snare; the other two pa-
tients underwent surgery, one of whom had concomi-
tant aortic valve replacement. Endpoint data of adverse 
events are shown in Table 2.
202)  
Nevertheless, this initial study shows substantial draw-
backs: 12.3% of patients had serious procedural com-
plications and 2.2% of attempted implantations result-
ed in cardiovascular surgical intervention due to device-
related complications. Therefore, a substantial learning 
curve must be considered in association with device im-
plantation. The primary efficiacy estimate of the PROT-
ECT-AF-study is less precise, due to the small number 
of participants, and nearly 30% of patients receiving de-
vices had a CHADS2 score of 1, and were therefore can-
didates for aspirin therapy without warfarin, even with-
out LAA occlusion.
203) 
 
The AMPLATZER Cardiac Plug system 
The AMPLATZER Cardiac Plug (ACP) is a transca-
Table 2. Results of the PROTECT-AF-Study
202): adverse events
  Intervention 
(n=463) (%) 
Control 
(n=244) (%)
Serious pericardial effusion*  22 (4.8)  0 
Major bleeding
†  16 (3.5)  10 (4.1) 
Procedure related ischemic stroke  05 (1.1)  0 
Device embolisation  03 (0.6)  0 
Hemorrhagic stroke
‡  01 (0·2)  06 (2·5) 
Other
§  02 (0·4)  0 
*Defined as the need for percutaneous or surgical drainage.  †Major 
bleeding is defined as a bleeding event that required at least 2 units 
of packed red blood cells or surgery to correct. ‡Of the seven he-
morhagic strokes, six resulted in death (intervention group, n=1;
control group, n=5). §An oesophageal tear and a procedurerelated 
arrhythmia 
 
Fig. 2. The AMPLATZER Cardiac Plug (ACP). On the right, the ideal position within the LAA is sketched. The lobe of the device is
anchored in the “landing zone” 1-2 cm distal of the LAA orifice, while the disc fully covers the outer shape and enables endothelialization
from the surrounding atrial wall. These images were provided by, and are property of AGA, Inc., Minneapolis, MN, USA. LAA: left atrial
appendage.  
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theter, self-expanding device constructed from a nitinol 
mesh and polyester patch (Fig. 2). The ACP consists of a 
lobe and a disc connected by a central waist. It is availa-
ble in eight diameter sizes (16, 18, 20, 22, 24, 26, 28, 
and 30 mm). The lobe has stabilizing wires to improve 
device placement and retention. The device has thread-
ed screw attachments at each end for connection to the 
delivery and loading cable. Radio-opaque markers at 
each end and at the stabilizing wires assist with fluo-
roscopic positioning. The ACP is a further development 
based on the AMPLATZER double-disk septal occluder, 
which was designed for closure of atrial septal defects 
and patent foramen ovale. In principle, this device can 
also be used for occlusion of the LAA; however, results 
of a feasibility trial were disappointing, as an emboliza-
tion occured in one of 16 patients.
204) The currently un-
published initial experience with ACP is encouraging. 
Its implantation is rather demanding technically, how-
ever, the disadvantages and risks associated with use of 
the PLAATO system are apparently eliminated (Fig. 3). 
A multicenter prospective registry trial to evaluate tech-
nical and short term success is approaching. 
 
Concerns Over Left Atrial  
Appendage Closure 
 
Controversy persists in regard to the risks and benefits 
of LAA occlusion for prevention of embolic stroke. 
Adverse hemodynamic and physiological effects may 
result from LAA obliteration.
205) Fluid retention is a 
potential late complication of LAA occlusion. Human 
atrial appendages contain 30% of total cardiac ANF.
30) 
Experimental data have shown that bilateral appenda-
gectomy in dogs eliminates ANF release and blunts re-
nal excretion of sodium and water during acute volume 
load.
206) Clinically evident postoperative fluid retention 
after the maze procedure with bilateral appendagectomy 
has been reported.
207) Another study of the maze proce-
dure reported on diminished ANF secretion accompani-
ed by increased need for postoperative diuretics and do-
pamine.
208) However, this effect was abolished when the 
right atrial appendage was preserved.
209) There are clues, 
however, that in the natural course of permanent atrial 
fibrillation, atrial degeneration may at least lead to de-
creased ANF secretion.
210) However, to date, many cases 
of surgical LAA exclusion with long term follow-up have 
not shown deleterious results. Pathophysiological conse-
quences of implanting a foreign body into the LAA re-
main to be fully elucidated. Small iatrogenic atrial septal 
defects can be created after transseptal puncture. They 
usually disappear within 6 months of the procedure. 
Furthermore, every implanted foreign material bears the 
risk of infection.
211) 
 
Conclusion 
 
AF is known to confer a risk of stroke; however, this 
risk is not homogeneous. Chronic oral anticoagulation 
as the prophylactic measure of choice has a number of 
major limitations associated with its narrow therapeutic 
range. A great deal of overlap evidently exists in throm-
boembolic stroke risk and risk of bleeding. Such over-
lapping risk creates a difficult management problem. 
Given the demonstrated risk of major bleeding, there is 
reason to be skeptical about net benefit when warfarin 
is used in some elderly patients with AF. Whether or 
not the needs of high-risk patients can be met by newer 
pharmacological and nonpharmacological antithrom-
botic/antiembolic therapies remains to be determined. 
It would seem that risk stratification schemes must be 
refined to incorporate data available from imaging stu-
dies that enhance predictive value for ischemic events 
and risk factors for bleeding. Occlusion of the LAA ori-
fice, therefore, offers a theoretically appealing way to re-
duce incidence of stroke in patients who cannot be an-
ticoagulated, or who developed stroke despite being on 
OAC. Nevertheless, there are limitations to this approach 
in that it cannot be easily applied prophylactically to 
Fig. 3. Images of the AMPLATZER Cardiac Plug (ACP) in situ. A: TOE. B: fluoroscopy after implantation. 
B  A 
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large numbers of patients. Concerns about procedural 
safety and need for long-term follow up should be ad-
dressed before this potentially important technology is 
widely deployed. 
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